Dr Ray O’Connor takes a look at some of the most recent clinical studies in therapeutics
Hypertension is a leading modifiable risk factor for cardiovascular disease and death. Based on the data from a nationwide survey in 2012-2015, around 245 million Chinese adults had hypertension, and the treatment and control rates were low at 41 per cent and 15 per cent, respectively. The use of evidence-based antihypertensive treatments, a key strategy for lowering blood pressure and reducing cardiovascular risk, is suboptimal in China.
Improving the performance of primary care doctors—the mainstay of the hypertension care workforce in China – is a key first step towards…